FORM 12B-25 NOTIFICATION OF LATE FILING
SEC FILE NUMBER
CUSIP NUMBER
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Check One): x Form 10-K Form 20-F Form 11-K Form 10-Q Form N-SAR
For Period Ended: December 31, 1999
Transition Report on Form 10-K
Transition Report on Form 20-F
Transition Report on Form 11-K
Transition Report on Form 10-A
Transition Report on Form N-SAR
For the Transition
Period Ended:
Read Instruction (on back page) Before Preparing Form, Please Print or Type. Nothing in this form shall be construed to imply that the Commissions have verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART I - REGISTRATION INFORMATION (Official Text)
Full Name of Registrant: IGENE Biotechnology, Inc.
Former Name if Applicable:
Address of Principal Executive Office (Street and Number): 9110 Red Branch Road
City, State and Zip Code: Columbia, Maryland 21045-2024
PART II - RULES 1b-25(b) AND (c) (Official Text)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) x
(a) The reasons described in reasonable detail in Part III
of this form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.
PART III - NARRATIVE (Official Text)
State below in reasonable detail the reasons why the Form 10-K, 11-K, 10-Q, N-SAR, or the transition report or portion
thereof, could not be filed within the prescribed time
period. (Attach Extra Sheets if Needed)
PART IV - OTHER INFORMATION (Official Text)
(1) Name and telephone number of person to contact in
regard to this notification
Stephen F. Hiu
410-997-2599
(2) Have all other periodic reports required under Section
13 or 15(d) of the Securities Exchange Act of 1934 of
Section 30 of the Investment Company Act of 1940 during
the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been
filed? If answer is no, identify report(s). YES
(3) Is it anticipated that any significant change in
results of operations from the corresponding period for
the last fiscal year will be reflected by the earnings
statement to be included in the subject report or
portion thereof?
NO
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state
the reasons why a reasonable estimate of the results cannot
be made.
Name of Registrant as Specified in Charter: IGENE
Biotechnology, Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 17, 2000
By: /s/ Stephen F. Hiu, Ph.D., President
INSTRUCTIONS:
The form may be signed by an executive officer of the
registrant or by any other duly authorized
representative. The name and title of the person
signing the form shall be typed or printed beneath the
signature. If the statement is signed on behalf of the
registrant by an authorized representative (other than
an executive officer), evidence of the representative's
authority to sign on behalf of the registrant shall be
filed with the form.
ATTENTION
Intentional misstatements of omissions of fact
constitute Federal Criminal Violations (See 18 U.S.C.
1001).
GENERAL INSTRUCTIONS (Official Text)
1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of
the General Rules and Regulations under the Securities
Exchange Act of 1934.
2. One signed original and four conformed copies of this form
and amendments thereto must be completed and filed
with the Securities and Exchange Commission,
Washington, D.C. 20549, in accordance with Rule 0-3 of
the General Rules and Regulations under the Act. The
information contained in or filed with the form will
be made a matter of public record in the Commission
files.
3. A manually signed copy of the form and amendments thereto
shall be filed with each national securities exchange
on which any class of securities of the registrant is
registered.
4. Amendment to the notification must also be filed on Form 12b-
25 but need not restate information that has been
correctly furnished. The form shall be clearly
identified as an amendment notification.
5. Electronic Filers. This form shall not be used by
electronic filers unable to timely file a report solely due to
electronic difficulties. Filers unable to submit a
report within the time period prescribed due to
difficulties in electronic filing should comply with
either Rule 201 or Rule 202 of Regulation S-T (232.201
or 232.202 of this chapter) or apply for an adjustment
in filing date pursuant to Rule 13(b) of Regulation S-T
(232.13(b) of this chapter). (Amended by Sec Act Rel No.
7122, Esch Act Rel No. 35113, eff 1/30/95).
INDEPENDENT AUDITORS REPORT
March 15, 2000
Berenson & Company LLP
Certified Public Accounts and Consultants
135 West 50th Street
New York, NY 10020
212-977-6800
FAX: 212-245-3808 or 212-245-7098
berenson.com
email:info@berenson.com
1912 Sunderland Place, NW
Washington, DC 20036
202-331-1044
FAX: 202-331-1085
United States Security and
Exchange Commission
Washington, D.C. 20549
Re: Igene Biotechnology, Inc.
EIN: 52-1230461
To Whom It May Concern:
We are the independent auditors for Igene Biotechnology,
Inc. We are unable at this point in time to express an
opinion on the Company's December 31, 1999 financial
statements or review the 10KSB as Igene is awaiting the
outcome of significant subsequent events which could
impact the financial statement disclosures.
Respectfully yours,
/s/ Berenson & Company LLP |
